The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in national cancer institute of Canada clinical trials group non-small cell lung cancer chemotherapy trials

Journal of Thoracic Oncology

Volumn 5, Issue 5, 2010, Pages 640-648

  Wheatley Price, Paul ^a   Le Maître, Aurélie ^b   Ding, Keyue ^b   Leighl, Natasha ^a   Hirsh, Vera ^c   Seymour, Lesley ^b   Bezjak, Andrea ^a   Shepherd, Frances A ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Chemotherapy; Non small cell lung cancer; Sex

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; REBIMASTAT;

ADJUVANT CHEMOTHERAPY; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; COMORBIDITY; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; NAUSEA AND VOMITING; NEUROPATHY; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SEX DIFFERENCE; STOMATITIS; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 77951938613     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d40a1b     Document Type: Article

References (53)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Global Cancer Facts and Figures 2007. American Cancer Society. Available at: http://www.cancer.org/downloads/STT/Global-Cancer- Facts-and-Figures-2007- rev.pdf, 2007. Accessed March 17, 2009.
3. Canadian Cancer Statistics 2008. Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada, Provincial/Territorial Cancer Registries, Public Health Agency of Canada. Available at: www.ncic.cancer.ca, 2008. Accessed March 17, 2009.
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
5. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002;13: 1087-1093.
6. Tammemagi CM, Neslund-Dudas C, Simoff M, et al. In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol 2004;57:597-609.
7. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-17.
8. Zalcberg J, Kerr D, Seymour L, et al. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer 1998;34:1871-1875.
9. Singh S, Parulekar W, Murray N, et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 2005;23:850-856.
10. Sloan JA, Loprinzi CL, Novotny PJ, et al. Sex differences in fluorouracil- induced stomatitis. J Clin Oncol 2000;18:412-420.
11. Badwe RA, Patil PK, Bhansali MS, et al. Impact of age and sex on survival after curative resection for carcinoma of the esophagus. Cancer 1994;74:2425-2429.
12. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19: 3622-3634.
13. Franco EL, Dib LL, Pinto DS, et al. Race and gender influences on the survival of patients with mouth cancer. J Clin Epidemiol 1993; 46:37-46.
14. McArdle CS, McMillan DC, Hole DJ. Male gender adversely affects survival following surgery for colorectal cancer. Br J Surg 2003;90:711-715.
15. Woloshin S, Schwartz LM, Welch HG. The risk of death by age, sex, and smoking status in the United States: putting health risks in context. J Natl Cancer Inst 2008;100:845-853.
16. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-1626.
17. Albain KS, Unger J, Gotay CC, et al. Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials. J Clin Oncol 2007; 25:Abstract 7549.
18. Belani CP, Von Pawel J, Pluzanska A, et al. Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine- cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): analyses by gender. Lung Cancer 2006;49S:235-236.
19. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986;4:702-709.
20. Mandrekar SJ, Schild SE, Hillman SL, et al. A pooled analysis of 11 NCCTG advanced stage non-small cell lung cancer (NSCLC) trials reveals the importance of baseline blood counts on clinical outcomes. J Clin Oncol 2005;23:Abstract 7193.
21. Visbal AL, Williams BA, Nichols FC III, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004;78:209 -215; discussion 215.
22. Wakelee HA, Wang W, Schiller JH, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 2006;1:441-446.
23. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597. (Pubitemid 41007845)
24. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3025-3034.
25. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR. 18. J Clin Oncol 2005;23:2831-2839.
26. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
28. Common Toxicity Criteria (CTC) version 2.0. Available at: http:// ctep.cancer.gov/forms/CTCv20-4-30-992.pdf. Accessed March 17, 2009.
29. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
30. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994;30A:635-642.
31. Osoba D, Bezjak A, Brundage M, et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005;41:280-287.
32. Paesmans M, Sculier JP, Lecomte J, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523-533.
33. Spiegelman D, Maurer LH, Ware JH, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 1989;7:344-354.
34. Efficace F, Bottomley A, Smit EF, et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in nonsmall- cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 2006;17:1698-1704.
35. Hoang T, Xu R, Schiller JH, et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol 2005;23:175-183.
36. Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006;14:354-360.
37. Lundh Hagelin C, Seiger A, Furst CJ. Quality of life in terminal care-with special reference to age, gender and marital status. Support Care Cancer 2006;14:320-328.
38. Siddiqui F, Kohl R, Swann S, et al. Gender differences in pretreatment quality of life in a prospective lung cancer trial. J Support Oncol 2008;6:33-39.
39. Thome B, Hallberg IR. Quality of life in older people with cancer-a gender perspective. Eur J Cancer Care (Engl) 2004;13:454-463.
40. Schmidt CE, Bestmann B, Kuchler T, et al. Gender differences in quality of life of patients with rectal cancer. A five-year prospective study. World J Surg 2005;29:1630-1641.
41. Tung HH, Wei J, Chang CY. Gender differences in quality of life for post coronary artery bypass grafting patients in Taiwan. J Nurs Res 2007;15:275-284.
42. Katsura H, Yamada K, Wakabayashi R, et al. Gender-associated differences in dyspnoea and health-related quality of life in patients with chronic obstructive pulmonary disease. Respirology 2007;12:427-432. (Pubitemid 47164778)
43. Akechi T, Kugaya A, Okamura H, et al. Fatigue and its associated factors in ambulatory cancer patients: a preliminary study. J Pain Symptom Manage 1999;17:42-48.
44. Pater JL, Zee B, Palmer M, et al. Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing the EORTC QLQ-C30. Support Care Cancer 1997;5:410-413.
45. Redeker NS, Lev EL, Ruggiero J. Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract 2000;14:275-290; discussion 291-298.
46. de Leeuw JR, de Graeff A, Ros WJ, et al. Prediction of depression 6 months to 3 years after treatment of head and neck cancer. Head Neck 2001;23:892-898. (Pubitemid 32862294)
47. Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 2000;18:893-903.
48. Gandhi M, Aweeka F, Greenblatt RM, et al. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004;44:499-523.
49. Calvert AH, Egorin MJ. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur J Cancer 2002; 38:11-16.
50. Dooley MJ, Poole SG, Rischin D, et al. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer 2002;38:44-51.
51. Joerger M, Huitema AD, van den Bongard DH, et al. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors. Clin Cancer Res 2006;12:2150-2157.
52. Ou SI, Ziogas A, Zell JA. Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): high percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity. J Clin Oncol 2008;26:Abstract 8004.
53. Tsao MS, Sakurada A, Aviel-Ronen S, et al. Impact of EGFR tyrosine kinase domain mutations on adjuvant chemotherapy in early stage non-small cell lung cancer (NSCLC). J Thorac Oncol 2009;4:S351.